---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-193957"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2026-04-30T23:59:59+00:00"
generated_at: "2026-05-15T01:04:21.822060+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kymera reports Q1 net loss $69.2M; Gilead licenses KT-200 for $45M milestone

## Summary
- Net loss $69.2M in Q1 2026, vs $65.6M in Q1 2025; cash $1.55B provides runway into 2029.
- Collaboration revenue $34.4M (all from Gilead), up from $22.1M in Q1 2025.
- Gilead exercised option to license KT-200 (oral CDK2 degrader), triggering a $45M milestone payment.
- KT-621 Phase 2b BROADEN2 (AD) data expected mid-2027; BREADTH (asthma) data late 2027; FDA Fast Track for asthma.
- KT-579 Phase 1 healthy volunteer trial ongoing; data expected in 2H26; KT-485/SAR447971 IND complete, clinical entry 2026.

## SEC filing metadata
- accession: 0001193125-26-193957
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2026-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312526193957/0001193125-26-193957-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312526193957/kymr-20260430.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-193957
- JSON: https://secwatch.observer/filing/0001193125-26-193957.json
- Plain text: https://secwatch.observer/filing/0001193125-26-193957.txt

## Key facts
- Earnings Releases
  Kymera Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026.
  - Period: the first quarter ended March 31, 2026
  - Result: reported results
  source text: On April 30, 2026, Kymera Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815442/000119312526193957/0001193125-26-193957-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.